A comparison between different postoperative treatment modalities of uterine carcinosarcoma

被引:69
作者
Menczer, J [1 ]
Levy, T
Piura, B
Chetrit, A
Altaras, M
Meirovitz, M
Glezerman, M
Fishman, A
机构
[1] E Wolfson Med Ctr, Dept Obstet & Gynecol, Gynecol Oncol Unit, Holon, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel
[4] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
[5] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy, Canc & Radiat Epidemiol Unit, IL-52621 Tel Hashomer, Israel
[6] Sapir Med Ctr, Kefar Sava, Israel
关键词
carcinosarcoma; chemotherapy; radiotherapy; sequential therapy;
D O I
10.1016/j.ygyno.2004.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Uterine carcinosarcomas are highly aggressive neoplastris with no established effective adjuvant therapy. The aim of the present study was to compare between the outcome in three medical institutions in each of which a different postoperative treatment modality was preferred, namely, chemotherapy in one, whole pelvic irradiation (WPI) in another, and sequential treatment (i.e., chemotherapy followed by WPI) in the third. Methods. The hospital records of all 49 uterine carcinosarcoma patients diagnosed and operated from 1995 to 2003 in the three institutions were reviewed. Non-parametric test was used to compare the median age between the treatment groups. Survival was calculated using the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression model was used to assess the effect of treatment type on survival after adjustment for stage. Results. Only about half of the patients (51%) had stage I at diagnosis and the majority of the patients (83.7%) had postoperative adjuvant treatment. The overall 5-year survival of the 41 patients that had postoperative treatment was 49.6%. The highest median survival and 5-year survival rate was observed in the sequential treatment group. Controlling for stage, this treatment modality was associated with a significant decrease in mortality of about 80% when compared to postoperative chemotherapy alone, and a non-significant decrease in mortality of about 50% when compared to WPI alone (HR = 0.20; 95% CI 0.04-0.99, P = 0.049 and HR = 0.50; 95% CI 0. 1-2.32, P = 0.4, respectively). Conclusions. The improved outcome in patients who received postoperative sequential treatment seems to indicate that further exploration of this treatment modality is justified. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:166 / 170
页数:5
相关论文
共 45 条
[1]   Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma [J].
Abargel, A ;
Avinoach, I ;
Kravtsov, V ;
Boaz, M ;
Glezerman, M ;
Menczer, J .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (02) :354-359
[2]  
Amant F, 2001, EUR J GYNAECOL ONCOL, V22, P194
[3]   A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus - A Gynecologic Oncology Group study [J].
Asbury, R ;
Blessing, JA ;
Podczaski, E ;
Ball, H .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (03) :306-307
[4]   Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999 [J].
Brooks, BE ;
Zhan, M ;
Cote, T ;
Baquet, CR .
GYNECOLOGIC ONCOLOGY, 2004, 93 (01) :204-208
[5]   Uterine sarcomas: The Curie Institut experience. Prognosis factors and adjuvant treatments [J].
Chauveinc, L ;
Deniaud, E ;
Plancher, C ;
Sastre, X ;
Amsani, F ;
de la Rochefordiere, A ;
Rozemberg, H ;
Clough, KB .
GYNECOLOGIC ONCOLOGY, 1999, 72 (02) :232-237
[6]   The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma [J].
Chi, DS ;
Mychalczak, B ;
Saigo, PE ;
Rescigno, J ;
Brown, CL .
GYNECOLOGIC ONCOLOGY, 1997, 65 (03) :493-498
[7]   Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: A gynecologic oncology group study [J].
Currie, JL ;
Blessing, JA ;
McGehee, R ;
Soper, JT ;
Berman, M .
GYNECOLOGIC ONCOLOGY, 1996, 61 (01) :94-96
[8]   Paclitaxel in the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study [J].
Curtin, JP ;
Blessing, JA ;
Soper, JT ;
DeGeest, K .
GYNECOLOGIC ONCOLOGY, 2001, 83 (02) :268-270
[9]  
ECHT G, 1990, CANCER, V66, P35, DOI 10.1002/1097-0142(19900701)66:1<35::AID-CNCR2820660108>3.0.CO
[10]  
2-V